Chemycal has been acquired by 3E
Learn MoreDiscover how Chemycal PRO helps you boosting your regulatory monitoring:
Medicare rule changes could trigger a spike in out-of-pocket drug costs for patients with multiple sclerosis.
Due to rules that restrict access and require patients to cover more of the cost, those without low-income subsidies can expect to spend almost $6,900 a year out of pocket for MS medicines, researchers reported.
CONTINUE READING ON www.upi.com
2013 © MyChemicalMonitoring. ALL Rights Reserved. About Us | Terms and Conditions